Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference
Liminal BioSciences Inc. (Nasdaq: LMNL), a clinical-stage biopharmaceutical company, announced that CEO Kenneth Galbraith will present at the Canaccord 40th Annual Growth Conference on August 13, 2020, from 2:00 PM to 2:25 PM EDT. The presentation will be accessible via live webcast on the company's website, with an archived replay available for at least seven days post-event.
The company is focused on developing treatments for fibrosis-related diseases and plans to start additional Phase 1 clinical trials for its lead drug candidate, fezagepras, in the second half of 2020.
- None.
- None.
LAVAL, QC, and CAMBRIDGE, England, Aug. 6, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at Canaccord 40th Annual Growth Conference on Thursday 13th August 2:00-2:25 PM (EDT).
The presentation will be webcast live on the webcast page of the Investors & Media section of the Company's website. An archived replay of the webcast will be available on the Company's website for at least 7 days after the live event concludes.
About Liminal BioSciences Inc.
Liminal BioSciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases that have high unmet medical need, including those related to fibrosis in respiratory, liver and kidney diseases. Liminal BioSciences has a deep understanding of both small molecule drug development as well as certain biological targets and pathways that have been implicated in the fibrotic process, including fatty acid receptors such as free fatty acid receptor 1, or FFAR1, (also known as G-protein-coupled receptor 40, or GPR40), a related receptor (G-protein-coupled receptor 84, or GPR84) and peroxisome proliferator-activated receptors, or PPARs. Our lead small molecule product candidate, fezagepras (PBI-4050), is expected to enter an additional Phase 1 clinical trial in 2H-2020 to evaluate multiple ascending doses of fezagepras in both healthy volunteers and patients, at daily dose exposures higher than those evaluated in our previously completed Phase 2 clinical trials. The optimal dose and dosing regimen of fezagepras is expected to be further evaluated in Phase 2 clinical trials in selected fibrosis indications to be initiated in 2021.
Liminal BioSciences has also leveraged its experience in bioseparation technologies through its subsidiary Prometic Bioproduction Inc. to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived product candidate is Ryplazim® (plasminogen), or Ryplazim®, for which the Company expects to resubmit a BLA in Q3 2020 with the FDA seeking approval to treat patients with congenital plasminogen deficiency. Ryplazim® (has been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for the treatment of congenital plasminogen deficiency.
Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19. Our Canadian center located in Winnipeg, Manitoba is licensed by the FDA and Health Canada, and is certified by the European Union and the Plasma Protein Therapeutics Association or PPTA. Our American center located in Amherst, New York is licensed by the State of New York and its' BLA submission is currently under review by the FDA.
Liminal BioSciences has active business operations in Canada, the United Kingdom and the United States.
Forward-Looking Statement
This press release contains forward-looking statements about Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties. Forward–looking information includes statements concerning, among other things, statements with respect to the timing of any planned BLA resubmission, development of R&D programs, and the timing of initiation of clinical trials.
These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. At this stage, the product candidates of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, Liminal BioSciences' ability to develop, manufacture, and successfully commercialize product candidates, if ever, the impact of the COVID-19 pandemic on its business operations, clinical development, regulatory activities and financial and other corporate impacts, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical trials, the ability of Liminal BioSciences' to take advantage of business opportunities in the pharmaceutical industry, uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the filings the Company makes with the U.S. Securities and Exchange Commission and Canadian Securities Commissions filings and reports, including in the Annual Report on Form 20-F for the year ended December 31, 2019 and future filings and reports by the Company from time to time. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Liminal BioSciences' business and the global economy. As a result, we cannot guarantee that any forward-looking statement will materialize. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. We assume no obligation to update any forward-looking statement contained in this Press Release even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
View original content:http://www.prnewswire.com/news-releases/liminal-biosciences-to-present-at-canaccord-40th-annual-growth-conference-301107930.html
SOURCE Liminal BioSciences Inc.
FAQ
When will Liminal BioSciences present at the Canaccord 40th Annual Growth Conference?
Who is the CEO of Liminal BioSciences?
What is the ticker symbol for Liminal BioSciences?
What is the focus of Liminal BioSciences?
What is the lead product candidate of Liminal BioSciences?
